Logo image of MIRM

MIRUM PHARMACEUTICALS INC (MIRM) Stock Fundamental Analysis

NASDAQ:MIRM - Nasdaq - US6047491013 - Common Stock - Currency: USD

50.34  -0.46 (-0.91%)

After market: 50.34 0 (0%)

Fundamental Rating

3

MIRM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. MIRM has a bad profitability rating. Also its financial health evaluation is rather negative. MIRM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MIRM has reported negative net income.
MIRM had a negative operating cash flow in the past year.
In the past 5 years MIRM always reported negative net income.
MIRM had negative operating cash flow in 4 of the past 5 years.
MIRM Yearly Net Income VS EBIT VS OCF VS FCFMIRM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

The Return On Assets of MIRM (-11.20%) is better than 83.48% of its industry peers.
With a decent Return On Equity value of -33.16%, MIRM is doing good in the industry, outperforming 75.40% of the companies in the same industry.
Industry RankSector Rank
ROA -11.2%
ROE -33.16%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
MIRM Yearly ROA, ROE, ROICMIRM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 77.10%, MIRM belongs to the top of the industry, outperforming 84.20% of the companies in the same industry.
MIRM's Gross Margin has declined in the last couple of years.
MIRM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
MIRM Yearly Profit, Operating, Gross MarginsMIRM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

3

2. Health

2.1 Basic Checks

MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MIRM has been increased compared to 1 year ago.
Compared to 5 years ago, MIRM has more shares outstanding
The debt/assets ratio for MIRM has been reduced compared to a year ago.
MIRM Yearly Shares OutstandingMIRM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MIRM Yearly Total Debt VS Total AssetsMIRM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 2.64 indicates that MIRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.64, MIRM is in the better half of the industry, outperforming 73.07% of the companies in the same industry.
MIRM has a Debt/Equity ratio of 1.32. This is a high value indicating a heavy dependency on external financing.
MIRM has a worse Debt to Equity ratio (1.32) than 80.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF N/A
Altman-Z 2.64
ROIC/WACCN/A
WACC8.39%
MIRM Yearly LT Debt VS Equity VS FCFMIRM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

MIRM has a Current Ratio of 3.22. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
MIRM has a Current ratio of 3.22. This is in the lower half of the industry: MIRM underperforms 63.73% of its industry peers.
MIRM has a Quick Ratio of 3.04. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
MIRM has a Quick ratio of 3.04. This is in the lower half of the industry: MIRM underperforms 63.20% of its industry peers.
Industry RankSector Rank
Current Ratio 3.22
Quick Ratio 3.04
MIRM Yearly Current Assets VS Current LiabilitesMIRM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.60% over the past year.
The Revenue has grown by 69.30% in the past year. This is a very strong growth!
MIRM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 160.12% yearly.
EPS 1Y (TTM)56.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.44%
Revenue 1Y (TTM)69.3%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%61.2%

3.2 Future

The Earnings Per Share is expected to grow by 25.81% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 21.39% on average over the next years. This is a very strong growth
EPS Next Y47.22%
EPS Next 2Y30.12%
EPS Next 3Y32%
EPS Next 5Y25.81%
Revenue Next Year34.14%
Revenue Next 2Y25.19%
Revenue Next 3Y23.23%
Revenue Next 5Y21.39%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MIRM Yearly Revenue VS EstimatesMIRM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
MIRM Yearly EPS VS EstimatesMIRM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MIRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MIRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRM Price Earnings VS Forward Price EarningsMIRM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIRM Per share dataMIRM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

MIRM's earnings are expected to grow with 32.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.12%
EPS Next 3Y32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MIRM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIRUM PHARMACEUTICALS INC

NASDAQ:MIRM (6/20/2025, 8:00:00 PM)

After market: 50.34 0 (0%)

50.34

-0.46 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners100.06%
Inst Owner Change3.39%
Ins Owners1.9%
Ins Owner Change0.41%
Market Cap2.49B
Analysts86.25
Price Target71.74 (42.51%)
Short Float %14.59%
Short Ratio14.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-44.37%
Min EPS beat(2)-99.42%
Max EPS beat(2)10.69%
EPS beat(4)2
Avg EPS beat(4)-15.53%
Min EPS beat(4)-99.42%
Max EPS beat(4)34.54%
EPS beat(8)3
Avg EPS beat(8)-45.87%
EPS beat(12)7
Avg EPS beat(12)-25.89%
EPS beat(16)9
Avg EPS beat(16)-60.95%
Revenue beat(2)2
Avg Revenue beat(2)6.03%
Min Revenue beat(2)0.89%
Max Revenue beat(2)11.17%
Revenue beat(4)4
Avg Revenue beat(4)5.39%
Min Revenue beat(4)0.89%
Max Revenue beat(4)11.17%
Revenue beat(8)7
Avg Revenue beat(8)7.58%
Revenue beat(12)10
Avg Revenue beat(12)6.64%
Revenue beat(16)12
Avg Revenue beat(16)31.03%
PT rev (1m)6.39%
PT rev (3m)9.21%
EPS NQ rev (1m)-22.92%
EPS NQ rev (3m)-80.29%
EPS NY rev (1m)0%
EPS NY rev (3m)-55.38%
Revenue NQ rev (1m)1.34%
Revenue NQ rev (3m)3.19%
Revenue NY rev (1m)1.38%
Revenue NY rev (3m)6.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.57
P/FCF N/A
P/OCF N/A
P/B 10.69
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.61
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS7.66
BVpS4.71
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.2%
ROE -33.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.1%
FCFM N/A
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.53%
Cap/Sales 5.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.22
Quick Ratio 3.04
Altman-Z 2.64
F-Score5
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)94.39%
Cap/Depr(5y)705.48%
Cap/Sales(3y)5.79%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.44%
EPS Next Y47.22%
EPS Next 2Y30.12%
EPS Next 3Y32%
EPS Next 5Y25.81%
Revenue 1Y (TTM)69.3%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%61.2%
Revenue Next Year34.14%
Revenue Next 2Y25.19%
Revenue Next 3Y23.23%
Revenue Next 5Y21.39%
EBIT growth 1Y29.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.56%
EBIT Next 3Y39.34%
EBIT Next 5YN/A
FCF growth 1Y75.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.01%
OCF growth 3YN/A
OCF growth 5YN/A